Programme Thesis
DayOne Accelerator is a 3-month hybrid, equity-free, fee-free programme run by Basel Area Business & Innovation (non-profit) to fast-track early-stage HealthTech and TechBio startups whose technology directly enables or accelerates steps inside pharma R&D workflows. It exists to serve as a structured entry-point into the Basel pharma ecosystem (Roche, Novartis, Lonza, Debiopharm, J&J) and to convert promising proof-of-concept tools into pharma-partnership-ready products. Post-accelerator, up to three standout companies can receive CHF 50k non-dilutive grant + CHF 50k in-kind support + 12 months office space via DayOne NEXT.
Selection Criteria
• ELIGIBILITY: Must enable/accelerate a step inside pharma R&D workflows — explicitly excludes consumer health apps, hospital ops, standalone drug development, and medical device hardware with no pharma R&D angle.
• STAGE: Pre-seed to Series A; < US$10M dilutive funding raised to date. Pre-incorporation is accepted.
• GEOGRAPHY: Open to any country worldwide.
• COHORT SIZE: 15 startups selected (2026 cohort; 2026 application pool had ~194 applicants from 40+ countries → ~33 shortlisted → 15 selected).
• SELECTION COMMITTEE COMPOSITION: Senior pharma executives (Director+ at Roche, Novartis, J&J, Debiopharm), life sciences investors (Nina Capital, Laconia, Kurma Partners, We Venture Capital, H Tree Capital), IP/regulatory experts, and domain technology leaders — this signals that reviewers will probe both scientific credibility AND commercial pharma fit.
• SCORING PRIORITIES (inferred from cohort profiles and FAQ language):
– Clarity and specificity of the pharma R&D problem addressed (who inside pharma buys it, which workflow step does it unlock).
– Differentiated technology with defensible IP or methodology.
– Evidence of traction or proof-of-concept (bench data, pilot agreement, published benchmark).
– Potential for Roche/Novartis/Basel pharma strategic relevance (proximity to Basel ecosystem or direct pipeline fit).
– Team credibility and coachability.
• APPLICATION FORM asks for: pitch deck, founder bio/CV, one-paragraph company description, problem/solution overview, technology description, current traction/PoC summary, roadmap and milestones.
Past Winners / Cohort Profiles
DayOne has run seven cohorts (branded 'Health 4.0' pre-2025, renamed to 'DayOne Accelerator' from 2025). Named alumni: InSilicoTrials (Italy, in silico clinical trial simulation), Risklick (Switzerland, AI clinical trial protocol optimization), TrialHub / FindMeCure (UK/Bulgaria, trial recruitment AI), Briya (Israel, liquid biopsy), Senseera (Israel, chromatin epigenomics, raised $7.1M seed post-cohort), Oncoustics (USA, AI ultrasound diagnostics), Theremia (France — notable: sole co-founder, EU-based, cohort 2024/25). 2025 cohort (announced Aug 2025) skews heavily toward AI: Lemna Bio (structure-first AI for molecular probes, similar computational biology vertical to the venture), Harmonic Discovery (Finland, AI multi-target small-molecule selectivity), Navis Bio (AI scientific intelligence for biopharma BD), StratifAI (Germany, AI multimodal biomarker precision oncology), OmniScience (US, AI clinical data science). Winner archetype: B2B SaaS/AI tool targeting pharma R&D decision-makers; technology is the product, not the molecule; at least one benchmark metric demonstrating superiority over baseline. Solo founders appear rarely but are not disqualifying (Oncoustics CEO Beth Rogozinski is a single leader; Theremia was co-founded by Iris Maréchal, France-based).
Ideal Candidate Fingerprint
The platonic ideal applicant is a 2–3 person founding team with at least one member who has pharma industry experience (as a scientist, BD lead, or clinical ops person), building a B2B software or computational tool that slots into an existing pharma R&D workflow step — ideally target validation, compound screening, biomarker discovery, or clinical trial operations. The tool has a functioning proof-of-concept with at least one pharma-relevant benchmark or a letter of intent from a major pharma, and the founders can articulate precisely which team inside Roche or Novartis would be the buyer and why existing tools fail them.
Recommended Framing
For Eniola Olutogun, the strongest frame is: 'the only resistance-prediction tool that works on day one of a drug program, before any crystal structure exists.' The 100% mutation coverage vs 17.6% for structure-limited tools is the killer stat for a Novartis or Roche reviewer who knows that novel-target programs spend years waiting for structural data before they can screen resistance risk — position the venture as solving a bottleneck that is invisible to standard tooling and that directly affects go/no-go decisions in pharma R&D. Frame the ESM-2 delta-embedding approach as TechBio-native computational infrastructure (not a one-off classifier), and anchor credibility to the Platinum benchmark result (AUROC 0.634, protein-grouped CV — methodology-rigorous), the Servier pilot in progress, and Paris-Saclay/Institut Pasteur collaborators. By May 2027, lead with AUROC ≥0.70 post-fine-tuning and pilot data, and pre-position the ask as: 'DayOne's Roche/Novartis network is the exact validation environment we need to prove generalisability across novel oncology and antiviral targets before scaling.'
Watch Out
1. SOLO FOUNDER: Most selected startups have 2+ co-founders. Eniola should explicitly address team-building plans in the application and name any scientific advisors or collaborators (Paris-Saclay, Institut Pasteur) to signal a network that compensates for the solo-founder risk.
2. ELIGIBILITY BOUNDARY — DRUG DEVELOPMENT VS. R&D TOOL: DayOne explicitly excludes 'therapeutic molecule or drug development projects.' Drug resistance prediction sits at the edge of this boundary and could be misread as drug development support rather than pharma R&D infrastructure. The application must frame the tool as a decision-support layer for pharma R&D teams (which targets/compounds to advance or deprioritise), not as drug development itself. The FAQ explicitly asks applicants to specify 'the specific pharma R&D problem it addresses and who inside the pharma company would buy or use it' — answer this with surgical precision.
3. AUROC 0.634 IS BELOW PUBLISHED SOTA: mCSM-lig achieves AUROC 0.70. This needs careful framing — emphasise that (a) the metric is on a harder, structure-free task, (b) 100% coverage is operationally more important than marginal AUROC gains, and (c) fine-tuning to ≥0.70 is the May 2027 milestone. Do not apply to the 2027 cohort until this milestone is reached.
4. NOT YET INCORPORATED: This is explicitly allowed (pre-incorporation is in scope), but the application should mention planned incorporation in France/Île-de-France to signal commitment.
5. COMPUTE AND WETLAB EXPECTATIONS: Selection committee includes pharma R&D executives who may expect some experimental validation. Eniola should pre-empt this by referencing the Platinum benchmark (357 curated resistance mutations) as the ground truth and the Servier pilot as the pharma-world validation pathway.